2026Year1Month13Danaher Group Officially Announces Key Personnel Changes in China's Diagnostic Platform:ChenSpikelet (Rosa) will step down as President of China Diagnostic Platform, and Yu Jing, former Vice President of Medtronic and General Manager of China Orthopedics and Neurosurgery Business, has officially taken over.

Chen Xiaosui at2021Year9Joined Danaher in the month, serving as Vice President and General Manager of Beckman Coulter Clinical Diagnostics in China, and President of Danaher China Diagnostics Platform. During his tenure, he promoted localization breakthroughs and policy adaptation for the diagnostics business. According to public information, under his leadership, Beckman Coulter became the first foreign-funded company to complete the localization of high-end assembly lines in China.IVDEnterprises, reagent localization accelerates simultaneously, platform80%The above diagnostic instruments have achieved local production in China. Facing multiple rounds of volume-based procurement (VBP) Policy challenges, Chen Xiaosui led the team to establish a dynamic response mechanism, and in the historically largest procurement of tumor markers and thyroid function tests led by Anhui, they expanded their market share against the trend, becoming the only leading foreign enterprise among the "Big Four" to successfully defend its position in multiple rounds of biochemical and immunoassay procurements. Internally, Danaher evaluated that she has "made significant and lasting contributions to the diagnostics business," especially in organizational restructuring.DBSDemonstrates exceptional leadership in system advancement and local innovation collaboration.

The successor, Yu Jing, has cross-industry and cross-field compound experience. SheGEMedical Group Employment Exceeds20Year, starting as a global procurement manager, and having served in roles such as Director of Clinical Systems Operations for the Asia-Pacific region, General Manager of the China Ultrasound Division, and Sales General Manager of the Non-Public Healthcare and Basic Healthcare Business Unit, leading over...1200People team, management scale reaches20Billion US dollars.

2019After joining Medtronic in [Year], Jing Yu served as the General Manager of China Orthopedics and Neurosurgery business, leading the advancement of the digital and intelligent transformation strategy: developmentAIBLEIntegrated Solution for Digital Orthopedics and Neurosurgery, Combining Smart Equipment Such as Surgical Robots, Navigation Systems, and Intraoperative ImagingAIData platform, promoting equipment interconnection and data interoperability; participating in the construction of the Changzhou Science Park Innovation Incubation Center, fostering local R&D and global resource integration;2025During the CIIE, its leadingAiBLEThe ecological family of products has completed commercialization, achieving a leap from "exhibition stand" to "operating table." According to a Medtronic announcement, Yu Jing left due to personal development reasons.2025Year11Left in the month, the innovative achievements he promoted, such as "Robotic Guidance for Laser Ablation Minimally Invasive Technology," have realized the deep integration of global intelligence and Chinese innovation.